The New England Journal of Medicine has published a perspective piece looking at the health insurance coverage structure for biologic drugs. The report, titled, Tier 4 Drugs and the Fraying Social Compact, examines the approach taken by some health insurers to deal with the high cost of the more expensive biotechnology drugs, particularly for cancer.
Instead of the more familiar co-payment, where a patient is charged a flat fee for certain types of procedure, co-insurance is proposed. This means that the patients is charged a share of the drug's cost. The study's authors Thomas Lee, an NEJM associate editor, and Ezekiel Emanuel, chairman of the department of bioethics at the National Institutes of Health, describe the approach to holding down premiums as "politically feasible." However, the NEJM article goes on to advocate a rationing system for treatment coverage, based on cost and effectiveness.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze